Mankind Pharma Limited has scheduled its 35th Annual General Meeting (AGM) for Tuesday, August 4, 2026, at 3:30 P.M. IST, to be held through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting will transact ordinary and special business, including the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, re-appointment of directors, and ratification of cost auditor remuneration. The company reported a 17% year-on-year increase in revenue from operations to ₹14,278 crores for FY2025-26, while consolidated profit after tax (PAT) stood at ₹1,938 crores.

AGM Schedule and E-Voting Details

Members eligible to vote are determined as of the cut-off date of Wednesday, July 29, 2026. Remote e-voting and the AGM participation schedule are outlined below:

The AGM notice and Annual Report for FY2025-26 are available on the company's website. Members who have not registered their e-mail addresses are requested to do so with their respective Depository Participants or the Registrar and Share Transfer Agent, KFin Technologies Limited.

AGM Business: Key Resolutions

The following business items are proposed for consideration at the 35th AGM:

Ordinary Business:

• Adoption of standalone and consolidated audited financial statements for the financial year ended March 31, 2026
• Re-appointment of Mr. Rajeev Juneja (DIN: 00283481), Vice Chairman & Managing Director, who retires by rotation

Special Business:

• Re-appointment of Mr. Satish Kumar Sharma (DIN: 07615602) as Whole Time Director for a further period of up to 5 (Five) consecutive years with effect from September 22, 2026, at a fixed salary of ₹ 1.32 crore per annum, subject to annual increments not exceeding 15% of the last remuneration drawn
• Ratification of remuneration of ₹ 25,50,000/- (Rupees Twenty Five Lakh Fifty Thousand only) plus applicable taxes payable to M/s M. K. Kulshrestha & Associates, Cost Accountants, for conducting the cost audit for FY2026-27

FY2026 Financial Highlights

The company reported strong financial performance for FY2025-26. The following table summarises key consolidated financial metrics:

On a standalone basis, revenue from continuing operations for FY2025-26 reached ₹10,421.18 crores, representing a 9.61% YoY increase from ₹9,507.41 crores in FY2024-25. Standalone PAT from continuing operations stood at ₹2,037.56 crores, compared to ₹1,724.76 crores in FY2024-25, with an EBITDA margin of 28.59% versus 25.50% in the prior year.

Business and Operational Highlights

The company's domestic business remained the core driver of growth, supported by the full-year consolidation impact of the BSV acquisition completed on October 23, 2024. Key operational developments during FY2025-26 include:

• BSV Integration: The integration of BSV's Women's Health Rx prescription business with Mankind was completed, resulting in optimised brand portfolio, field force and division restructuring. BSV's domestic business delivered double-digit growth driven by expansion of Gynaec coverage from 33K to 37K and continued focus on the IVF portfolio.
• Brand Acquisitions: The company acquired exclusive Indian market rights for Rivotril from Roche, strengthening its presence in CNS therapy for epilepsy and seizure disorders.
• Chronic Portfolio: Chronic share (excluding BSV) improved to 39% in FY2026 from 28% in FY2018, with a 190 bps increase in FY2026 alone, driven by strong growth in cardiac and anti-diabetic therapies.
• R&D Pipeline Milestones: Insulin Aspart successfully completed Phase III and is advancing towards commercialisation in India; GPR-119 (NCE) for anti-obesity and metabolic disorders progressed into advanced stages of Phase II clinical trials; a recombinant biosimilar in the IVF space (1st in India) is advancing to Phase III.
• Dividend: An interim dividend of ₹1 per equity share (face value ₹1 each), aggregating to ₹41.27 crores, was paid to equity shareholders during FY2025-26.
• Market Position: Mankind Pharma is the 4th largest pharmaceutical company in India by value with 4.7% market share and 2nd largest by volume with 6.1% market share, with a field force of 18,500+ and doctor coverage of 5 lakh+.

Director Profiles Proposed for Re-appointment

The following table provides key details of directors proposed for re-appointment at the 35th AGM:

The Board of Directors, on the recommendation of the Nomination and Remuneration Committee, has recommended the re-appointment of Mr. Rajeev Juneja by rotation and the re-appointment of Mr. Satish Kumar Sharma as Whole Time Director for a further period of up to 5 years with effect from September 22, 2026.

Mankind Pharma Limited achieved a 72.14% reduction in carbon emissions during the financial year 2025-26 compared to the base year FY 2020-21. The company sourced 91.69% of its electricity from renewable sources and processed 4,503 metric tonnes of plastic waste for recycling as part of its sustainability initiatives. These disclosures were made in the Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, which received reasonable assurance from SGS India Private Limited for core indicators.

The company reported that 69.33% of hazardous waste was disposed of through co-processing for energy recovery. Additionally, Mankind Pharma reduced ground water intensity by 37.26% from the base year FY 2019-20. The company has established a sustainability steering committee under the Risk Management Committee to oversee Environmental, Social, and Governance (ESG) matters.

Operational and Financial Overview

Mankind Pharma operates seven manufacturing plants and eight offices nationally, with two international offices. The company serves 28 states and 8 union territories in India, along with 38 international countries. Exports contributed 9.45% to the total turnover. The paid-up capital of the company stands at ₹41,28,28,328.

Employee Statistics

The company employed a total of 19,270 employees and 3,356 workers as of the end of the financial year. The workforce includes 507 female employees and 566 female workers. The gender diversity on the Board of Directors stands at 12.5%, with one female member out of eight directors. There were no differently abled workers reported, while the number of differently abled employees stood at three.

Environmental Performance

The company has set a target to become carbon neutral by FY 2029-30. Key environmental initiatives include the installation of solvent recovery plants and Zero Liquid Discharge (ZLD) facilities at API-1 and Udaipur in Rajasthan. The formulation facility in Sikkim has also been upgraded to ZLD. The company reported no fines or penalties for non-compliance with environmental laws during the year.

Governance and Assurance

The BRSR report was prepared on a standalone basis. SGS India Private Limited conducted an independent assessment, providing reasonable assurance for BRSR Core Indicators and limited assurance for non-core indicators. The company confirmed that it has not conducted any Life Cycle Perspective (LCA) assessments for its products but incorporates environmental considerations such as energy efficiency and waste management into its operations.